Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2020 May 15;395:114983. doi: 10.1016/j.taap.2020.114983

Corrigendum to “A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm” [Toxicology and Applied Pharmacology volume 394C (2020) 114961]

Bradley J Ridder a, Derek J Leishman b, Matthew Bridgland-Taylor c, Mohammadreza Samieegohar a, Xiaomei Han a, Wendy W Wu a, Aaron Randolph a, Phu Tran a, Jiansong Sheng d, Timm Danker e, Anders Lindqvist f, Daniel Konrad g, Simon Hebeisen g, Liudmila Polonchuk h, Evgenia Gissinger h, Muthukrishnan Renganathan i, Bryan Koci i, Haiyang Wei i, Jingsong Fan j, Paul Levesque j, Jae Kwagh j, John Imredy k, Jin Zhai k, Marc Rogers l, Edward Humphries l, Robert Kirby l, Sonja Stoelzle-Feix m, Nina Brinkwirth m, Maria Giustina Rotordam m, Nadine Becker m, Søren Friis m, Markus Rapedius m, Tom A Goetze m, Tim Strassmaier n, George Okeyo n, James Kramer o, Yuri Kuryshev o, Caiyun Wu o, Herbert Himmel p, Gary R Mirams q, David G Strauss a, Remi Bardenet r, Zhihua Li a,
PMCID: PMC7355225  PMID: 32247767

The authors regret that one affiliation address is mistaken in the published paper. Matthew Bridgland-Taylor's affiliation was incorrectly listed as Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom. The correct affiliation is Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.

The authors would like to apologise for any inconvenience caused.

RESOURCES